Sfoglia per Rivista GYNECOLOGIC ONCOLOGY
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)
2016-01-01 Marchetti, C; Ferrandina, G; Cormio, G; Gambino, A; Cecere, S; Lorusso, D; De Giorgi, U; Bogliolo, S; Fagotti, A; Mammoliti, S; Narducci, F; Bergamini, A; Scollo, P; Biglia, N; Breda, E; Tamberi, S; Marinaccio, M; Angioli, R; Salerno, L; Eusebi, Mc; Loizzi, V; Scambia, G; Panici, Pb
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
2020-01-01 Brewer, M; Angioli, R; Scambia, G; Lorusso, D; Terranova, C; Panici, Pb; Raspagliesi, F; Scollo, P; Plotti, F; Ferrandina, G; Salutari, V; Ricci, C; Braly, P; Holloway, R; Method, M; Madiyalakan, M; Bayever, E; Nicodemus, C
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
2011-01-01 Mangili, G; Sigismondi, C; Lorusso, D; Cormio, G; Scollo, P; Viganò, R; Gamucci, T; Candiani, M; Pignata, S
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
2020-01-01 Cecere, Sc; Giannone, G; Salutari, V; Arenare, L; Lorusso, D; Ronzino, G; Lauria, R; Cormio, G; Carella, C; Scollo, P; Ghizzoni, V; Raspagliesi, F; Di Napoli, M; Mazzoni, E; Marchetti, C; Bergamini, A; Orditura, M; Valabrega, G; Scambia, G; Maltese, G; De Matteis, E; Cardalesi, C; Loizzi, V; Boccia, S; Naglieri, E; Scandurra, G; Pignata, S
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer
2022-01-01 Bogani, Giorgio; Donato, Violante Di; Scambia, Giovanni; Landoni, Fabio; Ghezzi, Fabio; Muzii, Ludovico; Panici, Pierluigi Benedetti; Raspagliesi, Francesco; Scollo, Paolo
Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial
2019-01-01 Matulonis, ; U., A.; Walder, ; Nottrup, ; T., J.; Tinker, ; A., V.; Mahner, ; Gil-Martin, ; Fabbro, ; Banerjee, ; Wenham, ; R., M.; Woie, ; Gilbert, ; Harter, ; Casado, Herraez; Follana, ; Ledermann, ; J., A.; Leroy, ; Scollo, P; Lund, ; Malander, ; Fisher, ; Guy, ; Mirza, ; M., R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) | 1-gen-2016 | Marchetti, C; Ferrandina, G; Cormio, G; Gambino, A; Cecere, S; Lorusso, D; De Giorgi, U; Bogliolo, S; Fagotti, A; Mammoliti, S; Narducci, F; Bergamini, A; Scollo, P; Biglia, N; Breda, E; Tamberi, S; Marinaccio, M; Angioli, R; Salerno, L; Eusebi, Mc; Loizzi, V; Scambia, G; Panici, Pb | |
| Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study | 1-gen-2020 | Brewer, M; Angioli, R; Scambia, G; Lorusso, D; Terranova, C; Panici, Pb; Raspagliesi, F; Scollo, P; Plotti, F; Ferrandina, G; Salutari, V; Ricci, C; Braly, P; Holloway, R; Method, M; Madiyalakan, M; Bayever, E; Nicodemus, C | |
| Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. | 1-gen-2011 | Mangili, G; Sigismondi, C; Lorusso, D; Cormio, G; Scollo, P; Viganò, R; Gamucci, T; Candiani, M; Pignata, S | |
| Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome | 1-gen-2020 | Cecere, Sc; Giannone, G; Salutari, V; Arenare, L; Lorusso, D; Ronzino, G; Lauria, R; Cormio, G; Carella, C; Scollo, P; Ghizzoni, V; Raspagliesi, F; Di Napoli, M; Mazzoni, E; Marchetti, C; Bergamini, A; Orditura, M; Valabrega, G; Scambia, G; Maltese, G; De Matteis, E; Cardalesi, C; Loizzi, V; Boccia, S; Naglieri, E; Scandurra, G; Pignata, S | |
| Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer | 1-gen-2022 | Bogani, Giorgio; Donato, Violante Di; Scambia, Giovanni; Landoni, Fabio; Ghezzi, Fabio; Muzii, Ludovico; Panici, Pierluigi Benedetti; Raspagliesi, Francesco; Scollo, Paolo | |
| Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial | 1-gen-2019 | Matulonis, ; U., A.; Walder, ; Nottrup, ; T., J.; Tinker, ; A., V.; Mahner, ; Gil-Martin, ; Fabbro, ; Banerjee, ; Wenham, ; R., M.; Woie, ; Gilbert, ; Harter, ; Casado, Herraez; Follana, ; Ledermann, ; J., A.; Leroy, ; Scollo, P; Lund, ; Malander, ; Fisher, ; Guy, ; Mirza, ; M., R. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile